The Pandemic Hurt, But EY Expects More Biopharma Deal-Making In 2021
Life Sciences M&A Was Almost Half Of 2019’s Record
COVID-19 drove down both deal-making and biopharma “firepower” for part of 2020, but the industry began rebounding. This year should see significant bolt-on M&A activity and technology-driven alliances, according to EY.
